Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C24H32N4O2S |
| Molecular Weight | 440.601 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
O=C1CC2(CCCC2)CC(=O)N1CCCCN3CCN(CC3)C4=NSC5=C4C=CC=C5
InChI
InChIKey=ZFZPJDFBJFHYIV-UHFFFAOYSA-N
InChI=1S/C24H32N4O2S/c29-21-17-24(9-3-4-10-24)18-22(30)28(21)12-6-5-11-26-13-15-27(16-14-26)23-19-7-1-2-8-20(19)31-25-23/h1-2,7-8H,3-6,9-18H2
| Molecular Formula | C24H32N4O2S |
| Molecular Weight | 440.601 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Tiospirone (TSP) is an atypical antipsychotic drug. Tiaspirone appeared to be a promising antipsychotic agent as it didn`t cause extrapyramidal syndromes. It has 5HT-2 antagonistic properties as well as affinity for D2, 5HT-1a, 5HT-6 and sigma receptors. Tiospirone was in phase III clinical trials for the treatment of attention hyperactivity disorder with Mead Johnson in the USA but its development appears to have been discontinued.
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: CHEMBL214 Sources: https://www.ncbi.nlm.nih.gov/pubmed/11755134 |
4.65 nM [Ki] | ||
Target ID: CHEMBL225 Sources: https://www.ncbi.nlm.nih.gov/pubmed/10991983 |
74.0 nM [IC50] | ||
Target ID: CHEMBL3371 Sources: https://www.ncbi.nlm.nih.gov/pubmed/8522988 |
950.0 nM [Ki] |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Primary | Unknown Approved UseUnknown |
|||
| Primary | Unknown Approved UseUnknown |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Inverse agonist activity of atypical antipsychotic drugs at human 5-hydroxytryptamine2C receptors. | 2000-10 |
|
| Agonist and antagonist actions of antipsychotic agents at 5-HT1A receptors: a [35S]GTPgammaS binding study. | 1998-08-21 |
|
| Cloning, characterization, and chromosomal localization of a human 5-HT6 serotonin receptor. | 1996-01 |
|
| Binding of typical and atypical antipsychotic agents to 5-hydroxytryptamine-6 and 5-hydroxytryptamine-7 receptors. | 1994-03 |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/2728088
After a single 75 mg dose of tiospirone, demonstrable levels of dopamine binding activity were present. A variety of time points were sampled during the multiple dose study wherein subjects received 60 mg, t.i.d. for 28 days.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/2572973
Tiaspirone was found to be a competitive, reversible inhibitor of the sodium-dependent high-affinity choline uptake (SDHACU) by crude hippocampal and striatal synaptosomal preparations, giving IC50 values of respectively 3.69 microM and 1.14 uM.
| Substance Class |
Chemical
Created
by
admin
on
Edited
Wed Apr 02 09:34:26 GMT 2025
by
admin
on
Wed Apr 02 09:34:26 GMT 2025
|
| Record UNII |
35C6UMO5SR
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Official Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C28197
Created by
admin on Wed Apr 02 09:34:26 GMT 2025 , Edited by admin on Wed Apr 02 09:34:26 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
Tiospirone
Created by
admin on Wed Apr 02 09:34:26 GMT 2025 , Edited by admin on Wed Apr 02 09:34:26 GMT 2025
|
PRIMARY | |||
|
CHEMBL35057
Created by
admin on Wed Apr 02 09:34:26 GMT 2025 , Edited by admin on Wed Apr 02 09:34:26 GMT 2025
|
PRIMARY | |||
|
C73303
Created by
admin on Wed Apr 02 09:34:26 GMT 2025 , Edited by admin on Wed Apr 02 09:34:26 GMT 2025
|
PRIMARY | |||
|
SUB11092MIG
Created by
admin on Wed Apr 02 09:34:26 GMT 2025 , Edited by admin on Wed Apr 02 09:34:26 GMT 2025
|
PRIMARY | |||
|
100000077236
Created by
admin on Wed Apr 02 09:34:26 GMT 2025 , Edited by admin on Wed Apr 02 09:34:26 GMT 2025
|
PRIMARY | |||
|
87691-91-6
Created by
admin on Wed Apr 02 09:34:26 GMT 2025 , Edited by admin on Wed Apr 02 09:34:26 GMT 2025
|
PRIMARY | |||
|
C042709
Created by
admin on Wed Apr 02 09:34:26 GMT 2025 , Edited by admin on Wed Apr 02 09:34:26 GMT 2025
|
PRIMARY | |||
|
6035
Created by
admin on Wed Apr 02 09:34:26 GMT 2025 , Edited by admin on Wed Apr 02 09:34:26 GMT 2025
|
PRIMARY | |||
|
55752
Created by
admin on Wed Apr 02 09:34:26 GMT 2025 , Edited by admin on Wed Apr 02 09:34:26 GMT 2025
|
PRIMARY | |||
|
DTXSID90236558
Created by
admin on Wed Apr 02 09:34:26 GMT 2025 , Edited by admin on Wed Apr 02 09:34:26 GMT 2025
|
PRIMARY | |||
|
35C6UMO5SR
Created by
admin on Wed Apr 02 09:34:26 GMT 2025 , Edited by admin on Wed Apr 02 09:34:26 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
SALT/SOLVATE -> PARENT |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
METABOLITE -> PARENT |
URINE
|
||
|
METABOLITE -> PARENT |
URINE
|
||
|
METABOLITE -> PARENT |
URINE
|
||
|
METABOLITE -> PARENT |
URINE
|
||
|
METABOLITE -> PARENT |
URINE
|
||
|
METABOLITE -> PARENT |
URINE
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |